Gujarat Themis Biosyn Ltd - Stock Valuation and Financial Performance

BSE: 506879 | NSE: GUJTHEMIS | Pharmaceuticals & Drugs | Small Cap

Guj. Themis Biosyn Share Price

366 22.05 6.41%
as on 20-Sep'24 16:01

DeciZen - make an informed investing decision on Guj. Themis Biosyn

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Gujarat Themis Biosyn stock performance -

mw4me loader
P/E Ratio (SA):
72.94
Market Cap:
3,988.1 Cr.
52-wk low:
108.2
52-wk high:
389.9

Is Gujarat Themis Biosyn Ltd an attractive stock to invest in?

1. Is Gujarat Themis Biosyn Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gujarat Themis Biosyn Ltd is a good quality company.

2. Is Gujarat Themis Biosyn Ltd undervalued or overvalued?

The key valuation ratios of Gujarat Themis Biosyn Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Gujarat Themis Biosyn Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gujarat Themis Biosyn Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Guj. Themis Biosyn:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gujarat Themis Biosyn Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 113.7%80.4%54.7%42.2%44.9%86%67.9%67.9%61.5%45.4%-
Value Creation
Index
7.14.72.92.02.25.13.93.93.42.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 31.432.635.738.841.185.190.6115148170159
Sales YoY Gr.-3.8%9.4%8.7%5.8%107.4%6.4%26.8%29.2%14.4%-
Adj EPS 0.40.40.40.40.62.22.845.35.45
YoY Gr.--2.3%-7%-10%61.1%274.1%27.7%44.4%33%2.1%-
BVPS (₹) -0.10.40.81.11.73.96.49.513.718.520
Adj Net
Profit
4.84.74.43.96.423.730.243.65859.255
Cash Flow from Ops. 2.73.92.85.60.70.610.540.339.564.2-
Debt/CF from Ops. 2.20.91.40.18.812.90.3000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 20.6%32.8%23.3%14.4%
Adj EPS 32.2%56.4%25.2%2.1%
BVPSNA61.2%42.3%35%
Share Price 61.4% 130.9% 64.3% 219.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-156.7305.172.538.141.67853.850.445.933.826.1
Op. Profit
Mgn %
20.918.71716.117.937.444.550.549.646.446.5
Net Profit
Mgn %
15.314.312.21015.527.833.33839.134.834.3
Debt to
Equity
-7.70.90.50.10.30.20000-
Working Cap
Days
505578739214420422626724553
Cash Conv.
Cycle
-52-47-26-22-19275462472435

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 23.32%

Net Profit is growing at healthy rate in last 3 years 25.15%

Sales growth is good in last 4 quarters at 12.93%

Return on Equity has declined versus last 3 years average to 26.10%

Latest Financials - Gujarat Themis Biosyn Ltd.

Standalone Consolidated
TTM EPS (₹) 5 -
TTM Sales (₹ Cr.) 159 -
BVPS (₹.) 20 -
Reserves (₹ Cr.) 207 -
P/BV 18.27 -
PE 72.94 -
From the Market
52 Week Low / High (₹) 108.20 / 389.90
All Time Low / High (₹) 0.20 / 389.90
Market Cap (₹ Cr.) 3,988
Equity (₹ Cr.) 10.9
Face Value (₹) 1
Industry PE 47.6

Management X-Ray of Guj. Themis Biosyn:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.003.303.303.30
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Guj. Themis Biosyn

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales31333639418591115148170
Operating Expenses 25273033345350577591
Manufacturing Costs19212224263426313740
Material Costs001211115162636
Employee Cost 44445677810
Other Costs 1112222345
Operating Profit 666673240587479
Operating Profit Margin (%) 19.9%18.5%16.9%16.1%17.9%37.4%44.5%50.5%49.6%46.4%
Other Income 0000223474
Interest 0000011100
Depreciation 1111112234
Exceptional Items 0000000000
Profit Before Tax 555583141597779
Tax 00112811151920
Profit After Tax 554462430445859
PAT Margin (%) 14.6%14.2%12.3%10.0%15.6%27.8%33.3%38.0%39.1%34.8%
Adjusted EPS (₹)0.40.40.40.40.62.22.84.05.35.4
Dividend Payout Ratio (%)0%0%0%0%0%10%0%37%14%12%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund -14812194270103149201
Share Capital 7777777777
Reserves -8-31511356396142194
Minority Interest0000000000
Debt5120030000
Long Term Debt5110030000
Short Term Debt0010000000
Trade Payables667667471010
Others Liabilities 544391825272830
Total Liabilities 15152120337198137187241

Fixed Assets

Gross Block41421213182226284451
Accumulated Depreciation31321235791113
Net Fixed Assets1091111151719193338
CWIP 0000102132191
Investments 0000000000
Inventories001006612153
Trade Receivables227362015251827
Cash Equivalents 000422281298
Others Assets223292529569273
Total Assets 15152120337198137187241

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 34361111403964
PBT 555583141597779
Adjustment 2211-4100-20
Changes in Working Capital -4-2-3-0-2-24-20-4-154
Tax Paid 0-1-1-1-1-7-10-15-20-20
Cash Flow From Investing Activity 0-1-3-1-6-3-2-30-20-55
Capex 0-1-3-1-6-3-3-14-24-58
Net Investments 0000000000
Others 0000001-1633
Cash Flow From Financing Activity -3-30-452-5-14-13-9
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000000000
Dividend Paid 000000-2-10-12-7
Others -3-30-452-2-4-1-2
Net Cash Flow -1001003-460
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)N/A302.7172.6338.0641.8577.9953.8250.3545.9233.76
ROCE (%)N/A80.3854.6742.2244.8885.9667.8967.9161.5145.4
Asset Turnover Ratio2.042.221.981.851.541.641.070.980.920.79
PAT to CFO Conversion(x)0.60.80.751.50.170.040.370.910.671.08
Working Capital Days
Receivable Days21254746385670635348
Inventory Days545541424283219
Payable Days6,7846,3321,5551,0801,96721513311511499

Gujarat Themis Biosyn Ltd Stock News

Gujarat Themis Biosyn Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Guj. Themis Biosyn on 20-Sep-2024 16:01 is ₹366.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Sep-2024 16:01 the market cap of Guj. Themis Biosyn stood at ₹3,988.1.
The latest P/E ratio of Guj. Themis Biosyn as of 20-Sep-2024 16:01 is 72.94.
The latest P/B ratio of Guj. Themis Biosyn as of 20-Sep-2024 16:01 is 18.27.
The 52-week high of Guj. Themis Biosyn is ₹389.9 and the 52-week low is ₹108.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Guj. Themis Biosyn is ₹159.3 ( Cr.) .

About Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became India’s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.

Business area of the company

  • Pharmaceuticals & Drugs
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.